A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease
Latest Information Update: 18 Feb 2021
At a glance
- Drugs CT 1812 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Cognition Therapeutics
- 10 Feb 2021 Results presented in a Cognition Therapeutics media release.
- 10 Feb 2021 According to a Cognition Therapeutics media release, biomarker findings from the study have been published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
- 14 Mar 2018 According to a Cognition Therapeutics media release, results of this trial will be presented at the joint meeting of the International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) and the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) 2018.